

# Special Bulletin

For professional providers

November 27, 2023

## RP-019N Update: Change to New York Reimbursement Direction

Effective **January 1, 2024**, Highmark will move the New York reimbursement direction in **Reimbursement Policy-019N Drugs and Biologicals (RP-019N)** to the reimbursement direction for Delaware, Pennsylvania, and West Virginia that is currently outlined in the policy. This change will streamline and standardize how the plan reimburses for these services across all regions, and reduce administrative costs associated with maintaining different reimbursement methods.

To view the current version of RP-019N – including the reimbursement direction for Delaware, Pennsylvania, and West Virginia that will apply to New York – access the Provider Resource Center (PRC) via the provider portal, either [Availity®](#) or [NaviNet®](#). Once redirected to the PRC from the provider portal, select **CLAIMS, PAYMENT & REIMBURSEMENT** in the left-hand menu and then click **Reimbursement Policy**.

Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield is an independent licensee of the Blue Cross Blue Shield Association. All references to "Highmark" in this document are references to the Highmark company that is providing the member's health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.

Availity is an independent company that contracts with Highmark to offer provider portal services.

NaviNet is a registered trademark of NaviNet Inc., which is an independent company that provides secure, web-based portal between providers and health insurance Companies.

